Interlaboratory variation in the detection of clinically significant alloantibodies against human platelet alloantigens
暂无分享,去创建一个
This report describes the results of eight workshop exercises which were designed to test the proficiency of laboratories in the detection of antibodies to human platelet antigens (HPA). Detection of the most clinically significant alloantibody, anti‐HPA‐1a, is adequate. However, despite improvements in consistency of test results between laboratories over the last 3 years, there is still a high probability that clinically significant antibodies against other HPA alloantigens will not be detected.
[1] S. Panzer,et al. Rapid Typing for Human Platelet Antigen Systems ‐1, ‐2, ‐3 and ‐5 by PCR Amplification with Sequence‐Specific Primers , 1996, Vox sanguinis.
[2] A. Borne,et al. PLATELET AND NEUTROPHIL ALLOANTIGENS IN CLINICAL MEDICINE , 1996 .
[3] W. Ouwehand,et al. Sensitivity of the platelet immunofluorescence test (PIFT) and the MAIPA assay for the detection of platelet‐reactive alloantibodies: a report on two U.K. National Platelet Workshop Exercises 1 , 1994, Transfusion medicine.